Title: Value of EGFR and HER2 to predict the sensitivity of chemoradiotherapy in the esophageal squamous cell carcinoma
Abstract: Objective: To identify molecular markers epithelial growth factor receptor(EGFR) and human epithelial growth factor receptor-2(HER2) to predict the sensitivity of chemoradiotherapy(CRT)in the esophageal squamous cell carcinoma(ESCC).Methods: Viewed 59 patients with T3-4,N-any,and M-any ESCC treated with CRT.The expressions of EGFR,HER2,vascular endothelial growth factor(VEGF),and proliferating cell nuclear antigen(PCNA),p53,Ki-67 were investigated immunohistochemically in biopsy specimens obtained before treatment from all 59 patients.The immunoreactivities were compared with responsiveness to CRT,as evaluated by endoscopy. Results: The complete response rate(CR) of the tumor estimated by endoscopy was 63.6%(14/22)in patients in the EGFR positive group and 65.0%(13/20)in patients in the HER2 positive group,while the CR was 32.4%(12/37) in patients in the EGFR negative group and 33.3%(13/39)in patients in the HER2 negative group.The difference of CR between EGFR,HER2 positive and negative groups was significant(P=0.030,P=0.028).The immunoreactivities of the other molecular markers did not show a significant correlation with the responsiveness to CRT.Multiple logistic regression analysis revealed that positive immunostaining for EGFR and HER2 was significantly correlated with CR for CRT in esophageal squamous cell carcinoma. Conclusion: These results suggest that EGFR and HER2 may help to predict the response of tumor to CRT in esophageal squamous cell carcinoma.
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot